Expanded Access to Upadacitinib

Alopecia Areata, Atopic Dermatitis, Axial Spondyloarthritis, Crohn Disease, Giant Cell Arteritis, Hidradenitis Suppurativa, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Non-radiographic Axial, Non Segmental Vitiligo, Psoriatic Arthritis, Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus, Ulcerative Colitis

Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

No related papers found yet.